CareDx upgraded to Overweight from Equal Weight at Stephens

Stephens analyst Mason Carrico upgraded CareDx to Overweight from Equal Weight with a $10 price target citing increased visibility into operations and transplant volumes normalizing following Q3. The firm believes that clinician ordering patterns “have largely stabilized at this point” and that the company’s testing services business has found a new base to build on from here as a result.